ADC Development for Multiple Myeloma

Antibody-drug conjugates (ADCs) are a new type of immunotherapy that is being developed and tested in multiple myeloma (MM). Creative Biolabs offers comprehensive ADC development services for MM, which includes antibody preparation, linker-payload synthesis, antibody-drug conjugation, and in vitro efficacy tests. With unique expertise in both chemical synthesis and biochemistry, we are confident in offering one-stop ADC development services to meet your special needs.

Introduction of Multiple Myeloma

MM is a relatively rare hematologic disorder characterized by proliferation of plasma cells, primarily involving the bone marrow. MM accounts for approximately 1% of all malignancies and approximately 10% of hematologic neoplasms. MM may present with elevated Calcium levels, renal insufficiency, anemia, and bone lesions as well as elevated levels of serum M protein or urine M protein or both. MM has 2 clinical variants: solitary bone plasmacytoma and extramedullary plasmacytoma. The diagnosis of MM is predominantly based on osteolytic bone destruction, plasma cell infiltration of bone marrow, hypercalcemia, anemia, and chronic renal insufficiency. A plain X-ray survey has been used to detect lytic bone lesions, to stage, and to monitor the disease in patients with MM for many years. CT is also indicated for early detection of bone lesions that may not be detected by conventional radiographic skeletal survey. Besides, different MRI protocols, radionuclide imaging, and PET imaging methods have been proposed in MM.

MM disease. Fig.1 MM disease.

Current Treatment for Multiple Myeloma

Several classes of drugs including immunomodulatory agents, monoclonal antibodies (mAbs), and proteasome inhibitors have shifted the paradigm of treatment choices and outcomes for MM patients. Newer agents such as carfilzomib, bortezomib, lenalidomide, pomalidomide, and daratumumab, have contributed towards better survival outcomes. However, even with improved treatments, outcomes are poor for those with relapsed and refractory disease, highlighting the need for new treatments.

Nowadays, ADCs are emerging as a promising class of cancer biopharmaceuticals that combine the specificity of mAbs with the anti-tumor activity of cytotoxic agents. The successful development of clinically effective mAbs targeting over-expressed cell-surface proteins, such as SLAMF7 and CD38 in MM, suggests that this approach can also be applied to the development of ADCs.

Multimodality targeting of MM in the context of the bone marrow microenvironment. Fig.2 Multimodality targeting of MM in the context of the bone marrow microenvironment. (Bianchi, 2015)

What Can We Do for You?

ADC treatments may significantly extend disease-free and overall survival, with desirable safety profiles for MM patients. One of the most important aspects of developing antibody-based therapeutic in MM is target antigen selection. Recent years, efforts have been made by Creative Biolabs to identify valuable cell surface protein, develop mAbs against these interest targets and improve the anti-tumor activity of the mAb through conjugate with the payload. In addition to the mentioned aspect of antigen/antibody, the selection of a proper linker and drug is also important. To prevent premature release of the drug in the circulation, Creative Biolabs possesses different kinds of linkers which have a half-life in blood comparable to that of the antibody. Highly potent toxins and toxin derivatives targeting a variety of cellular pathways are also available according to our clients’ specific demands. Creative Biolabs now provides the ADC development services against the following targets, please refer to the corresponding fraction for detailed information.

ADC therapies are poised to aid in the treatment of MM. If you are interested in our ADC development services for MM, please feel free to contact us for more information.

Reference

  1. Bianchi, G.; et al. Promising therapies in multiple myeloma. Blood. 2015: blood-2015-03-575365.

For lab research use only, not for any in vivo human use.



Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.


Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.


Contact us
USA
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-357-2254
 Fax: 1-631-207-8356
 Email:
Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
 Tel: 44-207-097-1828
 Email:

Inquiry

Top